Relevant to this review, accumulating evidence shows that systemic Ang-(1-7) treatment improves both cardiovascular and metabolic outcomes in rodent models of cardiovascular-related diseases such as hypertension, diabetes, obesity, heart failure, atherosclerosis, stroke, and myocardial infarction [31,32,33,34,35,36]. This evidence concerns the gene ANG and diabetes mellitus.